Critical Survey: Tetralogic Pharmaceuticals Corp (TLOG) versus Its Rivals
Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Tetralogic Pharmaceuticals Corp to related businesses based on the strength of its risk, dividends, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Risk & Volatility
Tetralogic Pharmaceuticals Corp has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp’s competitors have a beta of 1.13, suggesting that their average share price is 13% more volatile than the S&P 500.
This table compares Tetralogic Pharmaceuticals Corp and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
|Tetralogic Pharmaceuticals Corp Competitors||-912.91%||-186.15%||-28.31%|
Institutional & Insider Ownership
2.7% of Tetralogic Pharmaceuticals Corp shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are owned by company insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Tetralogic Pharmaceuticals Corp and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Tetralogic Pharmaceuticals Corp||N/A||-$21.14 million||-0.03|
|Tetralogic Pharmaceuticals Corp Competitors||$224.58 million||$58.11 million||-1.01|
Tetralogic Pharmaceuticals Corp’s competitors have higher revenue and earnings than Tetralogic Pharmaceuticals Corp. Tetralogic Pharmaceuticals Corp is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings and target prices for Tetralogic Pharmaceuticals Corp and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
|Tetralogic Pharmaceuticals Corp Competitors||166||554||1216||16||2.55|
As a group, “Biotechnology” companies have a potential upside of 54.39%. Given Tetralogic Pharmaceuticals Corp’s competitors higher possible upside, analysts clearly believe Tetralogic Pharmaceuticals Corp has less favorable growth aspects than its competitors.
Tetralogic Pharmaceuticals Corp competitors beat Tetralogic Pharmaceuticals Corp on 5 of the 9 factors compared.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.